DE60120746D1 - Östrogenrezeptormodulatoren - Google Patents

Östrogenrezeptormodulatoren

Info

Publication number
DE60120746D1
DE60120746D1 DE60120746T DE60120746T DE60120746D1 DE 60120746 D1 DE60120746 D1 DE 60120746D1 DE 60120746 T DE60120746 T DE 60120746T DE 60120746 T DE60120746 T DE 60120746T DE 60120746 D1 DE60120746 D1 DE 60120746D1
Authority
DE
Germany
Prior art keywords
estrogen
receptor modulators
compounds
estrogen receptor
functioning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60120746T
Other languages
English (en)
Other versions
DE60120746T2 (de
Inventor
R Wilkening
Dann Leroy Parker
J Wildonger
Dongfang Meng
W Ratcliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60120746D1 publication Critical patent/DE60120746D1/de
Publication of DE60120746T2 publication Critical patent/DE60120746T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
DE60120746T 2000-11-27 2001-11-21 Östrogenrezeptormodulatoren Expired - Lifetime DE60120746T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25311400P 2000-11-27 2000-11-27
US253114P 2000-11-27
PCT/US2001/044010 WO2002041835A2 (en) 2000-11-27 2001-11-21 Estrogen receptor modulators

Publications (2)

Publication Number Publication Date
DE60120746D1 true DE60120746D1 (de) 2006-07-27
DE60120746T2 DE60120746T2 (de) 2007-05-24

Family

ID=22958920

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120746T Expired - Lifetime DE60120746T2 (de) 2000-11-27 2001-11-21 Östrogenrezeptormodulatoren

Country Status (8)

Country Link
EP (1) EP1339683B1 (de)
JP (1) JP4119246B2 (de)
AT (1) ATE329904T1 (de)
AU (2) AU2696502A (de)
CA (1) CA2428019C (de)
DE (1) DE60120746T2 (de)
ES (1) ES2265453T3 (de)
WO (1) WO2002041835A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2456150A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
CN100506795C (zh) * 2003-06-18 2009-07-01 中国科学院上海药物研究所 茚酮并吲哚类化合物、制备方法及它的医学用途
CN1839114A (zh) 2003-08-21 2006-09-27 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
US20070191438A1 (en) * 2004-04-06 2007-08-16 Rohrer Susan P Methods for the treatment of hypertension
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
WO2006062876A2 (en) 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
PT1855674E (pt) 2005-03-02 2014-10-08 Merck Canada Inc Composição para a inibição de catepsina k
EP1943224B1 (de) * 2005-10-05 2011-07-27 Merck Sharp & Dohme Corp. Östrogenrezeptormodulatoren
WO2007054257A2 (en) * 2005-11-08 2007-05-18 Laboratorios Del Dr. Esteve, S.A. Indene derivatives, their preparation and use as medicaments
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2675440B1 (de) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin-cysteinproteasehemmer
RU2500671C1 (ru) * 2012-08-07 2013-12-10 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" ПРОИЗВОДНОЕ 1',2',3'-ТРИМЕТОКСИБЕНЗО[4',5':4,5]-6,7-ДИГИДРОЦИКЛОГЕПТА-[3,2-f]-1H-1-МЕТИЛИНДОЛА И ЕГО ПРИМЕНЕНИЕ
RU2500670C1 (ru) * 2012-08-07 2013-12-10 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" ПРОИЗВОДНОЕ 1',2',3'-ТРИМЕТОКСИБЕНЗО[4',5':4,5]-6,7-ДИГИДРОЦИКЛОГЕПТА-[2,3-e]-1H-1-МЕТИЛИНДОЛА И ЕГО ПРИМЕНЕНИЕ
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
RU2692799C2 (ru) 2013-10-08 2019-06-27 Мерк Шарп И Доум Корп. Ингибиторы цистеинпротеаз катепсинов
CA2932224A1 (en) 2013-12-05 2015-06-11 Karo Pharma Ab Estrogen receptor beta agonists for use in treating mesothelioma
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors

Also Published As

Publication number Publication date
DE60120746T2 (de) 2007-05-24
CA2428019C (en) 2010-09-21
WO2002041835A3 (en) 2003-01-23
WO2002041835A2 (en) 2002-05-30
EP1339683B1 (de) 2006-06-14
ES2265453T3 (es) 2007-02-16
AU2696502A (en) 2002-06-03
EP1339683A2 (de) 2003-09-03
JP2004523486A (ja) 2004-08-05
ATE329904T1 (de) 2006-07-15
CA2428019A1 (en) 2002-05-30
AU2002226965B2 (en) 2006-05-18
EP1339683A4 (de) 2005-07-27
JP4119246B2 (ja) 2008-07-16

Similar Documents

Publication Publication Date Title
ATE524170T1 (de) Östrogenrezeptor modulatoren
ATE481397T1 (de) Modulatoren des östrogenrezeptors
DE60120746D1 (de) Östrogenrezeptormodulatoren
WO2002091993A3 (en) Estrogen receptor modulators
TW200631933A (en) Estrogen receptor modulators
MX2007006878A (es) Moduladores del receptor de estrogeno.
WO2002032377A3 (en) Estrogen receptor modulators
WO2004073612A3 (en) Estrogen receptor modulators
WO2004091488A3 (en) Estrogen receptor modulators
WO2002032373A3 (en) Estrogen receptor modulators
WO2006081152A3 (en) Estrogen receptor modulators
AU2003288644A1 (en) Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof
ATE517871T1 (de) Östrogenrezeptormodulatoren
WO2005097141A3 (en) Estrogen receptor modulators
WO2002058639A3 (en) Pyranoflavonoid compounds and their use as estrogen receptor modulators
WO2002053522A3 (en) Novel estrogen receptor ligands and methods i
AR039282A1 (es) Moduladores de receptores de estrogeno
WO2004073610A3 (en) Estrogen receptor modulators
WO2008057309A3 (en) Estrogen receptor modulators
WO2004026887A3 (en) Estrogen receptor modulators
WO2009059806A3 (en) Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine
MA32477B1 (fr) Derives estratrienes comprenant des bioisosteres heterocycliques pour le cycle a phenolique
DOP2002000384A (es) Moduladores de receptores estrogenicos.
DOP2005000224A (es) Moduladores de los receptores de estrogeno

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1339683

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1339683

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213